Henry Schein Lidocaine HCl 2% and Epinephrine 1:100,000 (Prescription Medicine) is a sterile isotonic solution containing a local anaesthetic agent, Lidocaine Hydrochloride, and a vasoconstrictor,Epinephrine (as bitartrate) and is administered parenterally by injection.
Therapeutic indications: Indicated for the production of local anaesthesia for dental procedures by nerve block or infiltration techniques.
Contraindications: Contraindicated in patients with a known history of hypersensitivity to local anaesthetics of the amide type or to any components of the injectable formulations. Special warnings and precautions for use: To minimize the likelihood of intravascular injection, aspiration should be performed before the local anaesthetic solution is injected. If blood is aspirated, the needle must be repositioned until no return of blood can be elicited by aspiration. Note, however, that the absence of blood in the syringe does not assure that intravascular injection will be avoided. Local anaesthetic procedures should be used with caution when there is inflammation and/or sepsis in the region of the proposed injection. Henry Schein Lidocaine HCl 2% and Epinephrine 1:100 000 contains potassium metabisulphite, a sulphite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulphite sensitivity in the general population is unknown and probably low. Sulphite sensitivity is seen more frequently in asthmatic than in non-asthmatic people. Henry Schein Lidocaine HCl 2% and Epinephrine 1:100 000 along with other local anaesthetics, is capable of producing methemoglobinemia. The American Heart Association has made the following recommendations regarding the use of local anaesthetics with vasoconstrictors in patients with ischemic heart disease: “Vasoconstrictor agents should be used in local anaesthesia solutions during dental practice only when it is clear that the procedure will be shortened or the analgesia rendered more profound.
Precautions: Lidocaine should be used with caution in patients with severe shock or heart block. Lidocaine should also be used with caution in patients with impaired cardiovascular function. Local anaesthetic solutions containing a vasoconstrictor should be used with caution in areas of the body supplied by end arteries or having otherwise compromised blood supply.Lidocaine should be used with caution in patients with hepatic disease, since amide-type local anaesthetics are metabolized by the liver. Lidocaine should be used with caution in persons with known drug sensitivities.
Interaction with other medicines and other forms of interaction: The administration of local anaesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe prolonged hypotension or hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential. Concurrent administration of vasopressor drugs and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. As Henry Schein Lidocaine HCl 2% and Epinephrine 1:100 000 solutions contain a vasoconstrictor (epinephrine), concurrent use of either with a Beta-adrenergic blocking agent (propranolol, timolol, etc.) may result in dose-dependent hypertension and bradycardia with possible heart block.
Fertility, Pregnancy and lactation: Pregnancy Teratogenic Effects: Pregnancy Category B. Breast feeding: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lidocaine is administered to a nursing woman. Fertility: Studies of lidocaine in animals to evaluate the effect on fertility have not been conducted.
Effects on ability to drive and use machines: Besides the direct anaesthetic affect, local anaesthetics may have a very mild effect on mental function and co-ordination, even in the absence of overt CNS toxicity, and may temporarily impair locomotion and alertness.
Undesirable effects: Adverse experiences following the administration of lidocaine are similar in nature to those observed with other amide-type local anaesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels (which may be caused by excessive dosage, rapid absorption, unintended intravascular injection or slow metabolic degradation), injection technique, volume of injection, hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature.
Dose: Refer to datasheet for dosing and administration details.
For full information on dosage, contraindications, precautions, interactions and adverse effects please refer to the data sheet available at www.medsafe.govt.nz or by clicking on the link provided with this product. NZ Sponsor: Henry Schein Regional Limited, Auckland
NP21458 - Aug 2024